Návratnost kapitálu společnosti AC Immune SA
Jaká je hodnota metriky Návratnost kapitálu společnosti AC Immune SA?
Hodnota metriky Návratnost kapitálu společnosti AC Immune SA je -39.43%
Jaká je definice metriky Návratnost kapitálu?
Return on capital employed (ROCE) je finanční ukazatel, který měří rentabilitu společnosti a efektivitu společnosti ve využívání vlastního kapitálu.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
Návratnost kapitálu společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností AC Immune SA
Čemu se věnuje společnost AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Firmy s metrikou návratnost kapitálu podobnou společnosti AC Immune SA
- Hodnota metriky Návratnost kapitálu společnosti Entree Resources je -39.74%
- Hodnota metriky Návratnost kapitálu společnosti E-COM (Aus) Pty Ltd je -39.73%
- Hodnota metriky Návratnost kapitálu společnosti Good2 Go4 Corp je -39.66%
- Hodnota metriky Návratnost kapitálu společnosti Ascendis Pharma A/S je -39.57%
- Hodnota metriky Návratnost kapitálu společnosti Therealreal Inc je -39.56%
- Hodnota metriky Návratnost kapitálu společnosti Ascentage Pharma Grp Intl je -39.45%
- Hodnota metriky Návratnost kapitálu společnosti AC Immune SA je -39.43%
- Hodnota metriky Návratnost kapitálu společnosti Sangamo Therapeutics je -39.40%
- Hodnota metriky Návratnost kapitálu společnosti Churchill Capital Corp IV je -39.36%
- Hodnota metriky Návratnost kapitálu společnosti InflaRx N.V je -39.33%
- Hodnota metriky Návratnost kapitálu společnosti Fosterville South Exploration je -39.22%
- Hodnota metriky Návratnost kapitálu společnosti Inogen Inc je -39.17%
- Hodnota metriky Návratnost kapitálu společnosti China Zenix Auto International je -39.05%